China Pharma Univ. CDK2 compound 46

China Pharma Univ. CDK2 compound 46: sourced facts only. name: "In our work, we achieved a potent and selective CDK2 inhibitor 46 through virtual screening and systematic structural modification." [PMID:40107208]; target: "In our work, we achieved a potent and selective CDK2 inhibitor 46 through virtual screening and systematic structural modification." [PMID:40107208]; developer: "State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China; Institute of Innovative Drug Discovery and Development, China Pharmaceutical University, Nanjing, 211198, China." [PMID:40107208]; stage: "Compound 46 could arrest cell cycle, promote apoptosis, and induce senescence-related phenotypes for CCNE1-amplifed ovarian cancer OVCAR3 cell line, and also displayed potent antitumor activity against OVCAR3 xenografts." [PMID:40107208]